These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16908373)

  • 21. Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective.
    Lacombe Barrios J; Bégin P; Paradis L; Hatami A; Paradis J; Des Roches A
    J Am Acad Dermatol; 2013 Nov; 69(5):832-834. PubMed ID: 24124824
    [No Abstract]   [Full Text] [Related]  

  • 22. Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis.
    Sánchez-Ramón S; Eguíluz-Gracia I; Rodríguez-Mazariego ME; Paravisini A; Zubeldia-Ortuño JM; Gil-Herrera J; Fernández-Cruz E; Suárez-Fernández R
    J Investig Allergol Clin Immunol; 2013; 23(3):190-6. PubMed ID: 23967758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IgE autoantibodies in atopic dermatitis--occurrence of different antibodies against the CH3 and the CH4 epitopes of IgE.
    Czech W; Stadler BM; Schôpf E; Kapp A
    Allergy; 1995 Mar; 50(3):243-8. PubMed ID: 7545880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe refractory atopic dermatitis with elevated serum IgE treated with omalizumab.
    Switlyk SA; Taylor AL; Gaertner EM
    Cutis; 2017 Apr; 99(4):E6-E8. PubMed ID: 28492605
    [No Abstract]   [Full Text] [Related]  

  • 25. The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis.
    Silverberg JI; Kantor R
    Dermatol Clin; 2017 Jul; 35(3):327-334. PubMed ID: 28577802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of omalizumab in patients with food allergy.
    Rafi A; Do LT; Katz R; Sheinkopf LE; Simons CW; Klaustermeyer W
    Allergy Asthma Proc; 2010; 31(1):76-83. PubMed ID: 20167148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders.
    Schulman ES
    Am J Respir Crit Care Med; 2001 Oct; 164(8 Pt 2):S6-11. PubMed ID: 11704611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating atopic asthma with the anti-IgE monoclonal antibody.
    D'Amato G
    Monaldi Arch Chest Dis; 2002 Apr; 57(2):117-9. PubMed ID: 12357840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure of omalizumab for treatment of severe adult atopic dermatitis.
    Krathen RA; Hsu S
    J Am Acad Dermatol; 2005 Aug; 53(2):338-40. PubMed ID: 16021135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-IgE autoantibody in patients with atopic dermatitis.
    Nawata Y; Koike T; Hosokawa H; Tomioka H; Yoshida S
    J Immunol; 1985 Jul; 135(1):478-82. PubMed ID: 3873495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
    Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
    Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Innovative therapies for asthma: anti-IgE -- the future?
    Weinberger M
    Paediatr Respir Rev; 2004; 5 Suppl A():S115-8. PubMed ID: 14980255
    [No Abstract]   [Full Text] [Related]  

  • 33. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines.
    Hotze M; Baurecht H; Rodríguez E; Chapman-Rothe N; Ollert M; Fölster-Holst R; Adamski J; Illig T; Ring J; Weidinger S
    Allergy; 2014 Jan; 69(1):132-5. PubMed ID: 24111531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omalizumab beyond asthma.
    Sanchez J; Ramirez R; Diez S; Sus S; Echenique A; Olivares M; Cardona R
    Allergol Immunopathol (Madr); 2012; 40(5):306-15. PubMed ID: 22264640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
    Dewilde S; Turk F; Tambour M; Sandström T
    Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results.
    van den Berge M; Pauw RG; de Monchy JG; van Minnen CA; Postma DS; Kerstjens HA
    Chest; 2011 Jan; 139(1):190-3. PubMed ID: 21208879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases.
    Toledo F; Silvestre JF; Muñoz C
    J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1325-7. PubMed ID: 22050044
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of anti-IgE therapy in patients with atopic dermatitis.
    Vigo PG; Girgis KR; Pfuetze BL; Critchlow ME; Fisher J; Hussain I
    J Am Acad Dermatol; 2006 Jul; 55(1):168-70. PubMed ID: 16781320
    [No Abstract]   [Full Text] [Related]  

  • 39. Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome.
    Sogkas G; Hirsch S; Jablonka A; Witte T; Schmidt RE; Atschekzei F
    Clin Immunol; 2020 Jun; 215():108452. PubMed ID: 32360519
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab.
    Mirkina I; Schweighoffer T; Kricek F
    Immunol Lett; 2007 Apr; 109(2):120-8. PubMed ID: 17368811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.